List of Peptide Therapies Companies in Canada - 11

Founded in 2017, 48Hour Discovery (48HD) has a powerful technology platform for peptide-based drug discovery. We are reducing the cost, time, and risk of developing new therapies with our innovative target screening strategy to quickly identify the best and most promising drug leads.

Arch works closely with the scientific community, universities and research institutions to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors. The company holds a strong patent portfolio of new drug candidates to prevent inflammation and organ injury. Arch’s Phase I and Phase II clinical trials led to LSALT peptide (Metablok), being the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving fifty-five hospitals across Canada. • Arch scientists described a novel mechanism of action for organ inflammation in the journal Cell. • Arch scientists identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil (white blood cell) adhesion receptor in the lungs, kidneys and liver. • DPEP1 was shown to be the target of LSALT peptide (Metablok), the Company’s lead drug candidate targeting inflammation in the lungs and kidneys. Arch is currently working to advance LSALT peptide through the production of additional human safety and efficacy data in a Phase II trial to prevent IRI-acute kidney injury (AKI). Please follow the company on LinkedIn, and subscribe at the website for the latest science and investor news.

Atorvia is a pre-clinical stage biopharmaceutical company on a mission to transform outcomes for patients with organ failure, starting with the kidney. Headquartered in Ottawa, ON, Atorvia is advancing a pipeline of technologies that will disrupt the existing organ failure landscape and transform outcomes for patients. Atorvia's lead program is focused on critical protein:protein interactions that trigger cell death and kidney failure. A first-in-class synthetic peptide therapeutic is in development with an initial indication in Acute Kidney Injury (AKI). AKI is a common and often fatal condition that leaves surviving patients with long term morbidities and can lead to chronic kidney disease, end stage renal disease, stroke & myocardial infarction. There is currently no treatment available.

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.

Feldan is a clinical-stage pharmaceutical company that specialized in the development of innovative treatments based on intracellular delivery. At the heart of our mission is the Feldan Shuttle, a unique peptide-based technology that provides access to intracellular targets beyond the reach of existing drugs, opening unprecedented opportunities to treat a wide range of diseases, notably respiratory and skin diseases. Since its inception, Feldan has been committed to innovation and redefining the quality of life for patients by improving the standard of care. As a team, we are driven to expand the horizons of therapeutic delivery and we take pride in our collective sense of accountability, collaboration and commitment to strive for excellence while having fun at work. Our dynamic team of experts in chemical engineering, cell biology, clinical development and business is united by our corporate culture and core values: ownership, teamwork, and fun. _ Feldan est une entreprise pharmaceutique spécialisée dans le développement de traitements innovants basés sur l’administration intracellulaire. Au cœur de notre mission se trouve le Feldan Shuttle, une technologie unique à base de peptides qui donne accès à des composantes intracellulaires hors de portée des médicaments existants, offrant ainsi des perspectives sans précédent pour le développement d’une nouvelle génération de traitements, notamment pour des maladies affectant la peau et les poumons. Depuis sa création, Feldan met l'accent sur l'innovation et a pour but de redéfinir la qualité de vie des patients en faisant évoluer les normes de soins. En tant qu’équipe, nous sommes motivés à étendre les possibilités de livraison intracellulaire et fiers de notre sens de l’engagement, de la collaboration et de l’excellence. Notre équipe d'experts en génie chimique, biologie cellulaire, développement clinique et affaires est unie par notre culture d'entreprise et nos valeurs: appropriation, travail d'équipe et plaisir.

We design ground-breaking therapies through precision-targeting of membrane receptors to bring hope to people living with autoimmune diseases. Dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases, our company was launched in 2020 with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics, and an exclusive global license from Strasbourg University on a technology and related know-how initially developed by Dr. Dominique Bagnard.

NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing innovative treatments for nervous system damage, due to injury or disease. NervGen’s lead drug candidate, NVG-291, is a first of its kind experimental drug administered by injection under the skin. NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory. NVG-291 entered Phase 1 clinical trials in 2021. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.

Soricimed is a privately-held, clinical stage company dedicated to developing effective and novel targeted treatments for cancer. Since the discovery of a unique protein found in the venomous saliva of the northern short-tailed shrew in 2005, the company is committed to developing effective, highly targeted delivery peptides and powerful therapeutics for several types of solid tumour cancers, making an impact on those living with often devastating conditions. General Information and Guidelines: Soricimed strives to create informative and engaging online communities that share information in meaningful ways. We welcome and encourage your participation and engagement in thoughtful and respectful discourse.

SYNG Pharmaceuticals Inc. (SYNG Pharma) is a pre-clinical stage biotechnology company dedicated to developing next generation diagnostic and therapeutic against endometriosis. The company is developing a novel peptide, SP011, to inhibit a target now known for its role in the proliferation of cells. SYNG Pharma has a potential to develop a treatment that would be a much needed alternative to currently available, partly ineffective, hormonal therapy. There are many other potential applications of SYNG Pharma technology including the treatment of fibroids and uterine sarcoma; breast and prostate cancer which may be further developed depending upon corporate interests and an opportunity for partnership.

Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. The company currently markets two medicines in HIV and has research programs in HIV, NASH, and Oncology.

Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life..